Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
LY2801653
96
CHF
CHF 96.00
In stock
SYN-1222-M0011 mgCHF 96.00
SYN-1222-M0055 mgCHF 215.00
SYN-1222-M01010 mgCHF 323.00
SYN-1222-M05050 mgCHF 898.00
SYN-1222-M100100 mgCHF 1'496.00
| Product Details | |
|---|---|
| Synonyms | LY-2801653; N-(3-Fluoro-4-((1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide |
| Product Type | Chemical |
| Properties | |
| Formula | C30H22F2N6O3 |
| MW | 552.5 |
| CAS | 1206799-15-6 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: c-MET | Kinase Group: RTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | QHADVLVFMKEIIP-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R and other oncoproteins. It displays anti-tumour activities in mouse xenograft models. In vitro, LY2801653 has an IC50 for inhibition of MET phosphorylation between 35.2-59.2nM. LY2801653 was found in nonclinical models to also have potent activity against several other receptor tyrosine oncokinases including FLT3, AXL, MERTK, TEK, ROS1, DDR1/2 and against the serine/threonine kinases MKNK1/2.
Product References
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models: S.B. Yan, et al.; Invest. New Drugs. 31, 833 (2013)
Related Products
